Missing/wrong data?
Log in to edit
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
scientific article published on 12 February 2018
Author/s
author: Xavier Pivot, Seock-Ah Im, Tomasz Sarosiek, Marek Wojtukiewicz
Work details
Publication date
February 12, 2018
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.